SI3325482T1 - Postopki za pripravo citotoksičnih benzodiazepinskih derivatov - Google Patents

Postopki za pripravo citotoksičnih benzodiazepinskih derivatov

Info

Publication number
SI3325482T1
SI3325482T1 SI201630923T SI201630923T SI3325482T1 SI 3325482 T1 SI3325482 T1 SI 3325482T1 SI 201630923 T SI201630923 T SI 201630923T SI 201630923 T SI201630923 T SI 201630923T SI 3325482 T1 SI3325482 T1 SI 3325482T1
Authority
SI
Slovenia
Prior art keywords
methods
benzodiazepine derivatives
cytotoxic benzodiazepine
preparing cytotoxic
preparing
Prior art date
Application number
SI201630923T
Other languages
English (en)
Inventor
Baudouin Gerard
Manami Shizuka
Michael Louis Miller
Richard A. Silva
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of SI3325482T1 publication Critical patent/SI3325482T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SI201630923T 2015-07-21 2016-07-21 Postopki za pripravo citotoksičnih benzodiazepinskih derivatov SI3325482T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562195023P 2015-07-21 2015-07-21
US201662327973P 2016-04-26 2016-04-26
EP16745598.9A EP3325482B1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
PCT/US2016/043414 WO2017015502A1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
SI3325482T1 true SI3325482T1 (sl) 2020-11-30

Family

ID=56557925

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201630578T SI3325483T1 (sl) 2015-07-21 2016-07-21 Metode priprave derivatov citotoksičnega benzodiazepina
SI201630923T SI3325482T1 (sl) 2015-07-21 2016-07-21 Postopki za pripravo citotoksičnih benzodiazepinskih derivatov

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201630578T SI3325483T1 (sl) 2015-07-21 2016-07-21 Metode priprave derivatov citotoksičnega benzodiazepina

Country Status (22)

Country Link
US (11) US10081640B2 (sl)
EP (7) EP3325483B1 (sl)
JP (8) JP2018522018A (sl)
KR (5) KR20240055903A (sl)
CN (5) CN113087763A (sl)
AU (7) AU2016297608B2 (sl)
CA (4) CA2992082A1 (sl)
CY (2) CY1122553T1 (sl)
DK (2) DK3325482T3 (sl)
ES (4) ES2820358T3 (sl)
HK (3) HK1252323A1 (sl)
HR (1) HRP20201479T1 (sl)
HU (1) HUE051541T2 (sl)
IL (10) IL305989A (sl)
LT (2) LT3325483T (sl)
PL (2) PL3325482T3 (sl)
PT (2) PT3325482T (sl)
RS (2) RS59806B1 (sl)
RU (3) RU2746322C2 (sl)
SG (2) SG10202106529XA (sl)
SI (2) SI3325483T1 (sl)
WO (3) WO2017015502A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113087763A (zh) 2015-07-21 2021-07-09 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
KR102609698B1 (ko) 2016-03-22 2023-12-04 에베 그룹 에. 탈너 게엠베하 기판을 결합하기 위한 방법 및 장치
EP3529269A2 (en) 2016-10-19 2019-08-28 Invenra, Inc. Antibody constructs
BR112019013107A2 (pt) 2016-12-22 2019-12-17 Univ Degli Studi Magna Graecia Catanzaro anticorpos, molécula de ligação, receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, linfócito, ácido nucleico, célula de hibridoma, método para a produção do anticorpo monoclonal e usos
ES2935346T3 (es) 2017-01-25 2023-03-06 Immunogen Inc Métodos para preparar derivados de benzodiazepina citotóxicos
CA3102349A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TW202033530A (zh) 2018-11-12 2020-09-16 美商伊繆諾金公司 製備細胞毒性苯并二氮呯衍生物之方法
TW202033498A (zh) * 2018-11-12 2020-09-16 美商伊繆諾金公司 製備細胞毒性苯二氮呯衍生物之方法
JP2022529583A (ja) * 2019-03-29 2022-06-23 イミュノジェン・インコーポレーテッド 異常細胞増殖を阻害するまたは増殖性疾患を治療するための細胞毒性ビス－ベンゾジアゼピン誘導体及び細胞結合剤とのその複合体

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860600A (en) 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US3763183A (en) 1972-07-10 1973-10-02 Sterling Drug Inc 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US4678784A (en) 1984-04-11 1987-07-07 Mcneilab, Inc. Method for the treatment of LHRH diseases and conditions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
CA2076465C (en) 1992-03-25 2002-11-26 Ravi V. J. Chari Cell binding agent conjugates of analogues and derivatives of cc-1065
PT1193270E (pt) 1998-08-27 2003-10-31 Spirogen Ltd Pirrolobenzodiazepinas
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
AU765588C (en) 1999-11-24 2004-12-16 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
CN100522955C (zh) 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
RU2338747C2 (ru) 2003-03-31 2008-11-20 Каунсил Оф Сайентифик Энд Индастриал Рисерч ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
RU2314309C2 (ru) 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
AU2003215810B2 (en) 2003-03-31 2009-06-18 Council Of Scientific And Industrial Research Pyrrolo((2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
WO2004087717A1 (en) 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents and process thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005040170A2 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
AU2003300718A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing pyrrolo(2, 1-c) (1, 4) benzodiazepine hybrids
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
EP1720881B9 (en) * 2004-03-01 2013-04-17 Spirogen Sàrl 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepins
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
GB0412492D0 (en) * 2004-06-04 2004-07-07 Sterix Ltd Compound
GB0508084D0 (en) * 2005-04-21 2005-06-01 Spirogen Ltd Pyrrolobenzodiazepines
DE602006011300D1 (de) 2005-04-21 2010-02-04 Spirogen Ltd Pyrrolobenzodiazepine
ATE427949T1 (de) 2005-10-05 2009-04-15 Spirogen Ltd 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung
US7763731B2 (en) * 2005-12-21 2010-07-27 Abbott Laboratories Anti-viral compounds
ES2374964T3 (es) 2006-01-25 2012-02-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina.
JP2009526778A (ja) 2006-02-13 2009-07-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法
MX2008015132A (es) 2006-05-30 2008-12-10 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
EP2188297B1 (en) 2007-08-01 2012-02-01 Council of Scientific & Industrial Research Pyrrolo [2,1-c][1, 4] benzodiazepine-glycoside prodrugs useful as a selective anti tumor agent
KR20100137585A (ko) 2008-04-30 2010-12-30 이뮤노젠 아이엔씨 강력한 복합체 및 친수성 링커
SG189811A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0822260D0 (en) * 2008-12-05 2009-01-14 Merten Christoph Assay
US8637558B2 (en) * 2008-12-30 2014-01-28 Industry-Academic Cooperation Foundation, Chosun University Thiazolidinedione derivative and use thereof
KR101984053B1 (ko) 2009-02-05 2019-05-30 이뮤노젠 아이엔씨 신규한 벤조디아제핀 유도체
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
EP2511260B1 (en) 2009-12-08 2015-07-29 Gifu University Aromatic compound, modification carrier that uses same and is used for synthesizing an oligonucleotide derivative, oligonucleotide derivative, and oligonucleotide construct
US8962279B2 (en) * 2009-12-30 2015-02-24 Intel Corporation Solid-phase chelators and electronic biosensors
LT3202460T (lt) * 2010-02-11 2019-10-10 Celgene Corporation Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus
EP3196212B1 (en) 2010-02-24 2020-06-03 ImmunoGen, Inc. Immunoconjugates comprising a folate receptor 1 antibody
NZ602933A (en) 2010-04-15 2014-09-26 Seattle Genetics Inc Pyrrolobenzodiazepines used to treat proliferative diseases
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
BR112012026801B8 (pt) 2010-04-15 2021-05-25 Medimmune Ltd conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
WO2012112708A1 (en) 2011-02-15 2012-08-23 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and methods of preparation
CN102234253B (zh) * 2011-06-02 2013-07-03 重庆莱美药业股份有限公司 一种制备非布索坦中间体的方法
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
JP6694811B2 (ja) 2013-10-04 2020-05-20 ノバルティス アーゲー ＲＮＡ干渉に使用するためのＲＮＡｉ剤用の３’末端キャップ
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
CN103664896B (zh) * 2013-11-25 2016-03-02 济南精合医药科技有限公司 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法
TW201613930A (en) 2014-09-03 2016-04-16 Immunogen Inc Cytotoxic benzodiazepine derivatives
RU2017110068A (ru) * 2014-09-03 2018-10-03 Иммуноджен, Инк. Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты
TWI697493B (zh) 2014-09-03 2020-07-01 美商免疫原公司 細胞毒性苯并二氮呯衍生物
CN113087763A (zh) 2015-07-21 2021-07-09 伊缪诺金公司 制备细胞毒性苯并二氮杂䓬衍生物的方法
EP3380525B1 (en) * 2015-11-25 2023-11-08 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof

Also Published As

Publication number Publication date
JP2018522018A (ja) 2018-08-09
US9890179B2 (en) 2018-02-13
CN108290895B (zh) 2021-03-19
HK1252322A1 (zh) 2019-05-24
US20210171546A1 (en) 2021-06-10
US20210171547A1 (en) 2021-06-10
IL286788A (en) 2021-10-31
DK3325482T3 (da) 2020-09-28
JP2022046542A (ja) 2022-03-23
EP3778602B1 (en) 2023-07-12
HK1252321A1 (zh) 2019-05-24
SG10202106529XA (en) 2021-07-29
IL286788B1 (en) 2023-09-01
KR102659706B1 (ko) 2024-04-23
IL276631B (en) 2021-10-31
AU2016297087A1 (en) 2018-02-08
AU2023202221A1 (en) 2023-05-04
AU2021203148B2 (en) 2023-01-12
IL294651B2 (en) 2024-02-01
IL256861B (en) 2020-08-31
ES2959741T3 (es) 2024-02-28
AU2021202403B2 (en) 2022-12-08
AU2016297607A1 (en) 2018-02-08
JP2018524387A (ja) 2018-08-30
JP2023162264A (ja) 2023-11-08
PL3325482T3 (pl) 2021-01-11
EP4286387A3 (en) 2024-02-21
IL294651A (en) 2022-09-01
IL256860B (en) 2020-08-31
US11420982B2 (en) 2022-08-23
PT3325483T (pt) 2020-01-15
HUE051541T2 (hu) 2021-03-01
EP4286387A2 (en) 2023-12-06
AU2016297608B2 (en) 2021-02-18
JP2018526340A (ja) 2018-09-13
CY1122553T1 (el) 2021-01-27
CA2991305A1 (en) 2017-01-26
US10081640B2 (en) 2018-09-25
RU2018105752A3 (sl) 2019-12-30
WO2017015502A8 (en) 2017-03-02
JP7337114B2 (ja) 2023-09-01
EP3778602A1 (en) 2021-02-17
JP7334228B2 (ja) 2023-08-28
RU2018105756A (ru) 2019-08-21
EP3325482B1 (en) 2020-06-24
US20190389883A1 (en) 2019-12-26
US9873708B2 (en) 2018-01-23
RU2018105752A (ru) 2019-08-21
SI3325483T1 (sl) 2020-03-31
AU2021203148A1 (en) 2021-06-10
CN108026103A (zh) 2018-05-11
CN113004288A (zh) 2021-06-22
IL276630B (en) 2021-06-30
EP3325485A1 (en) 2018-05-30
ES2820358T3 (es) 2021-04-20
IL294651B1 (en) 2023-10-01
LT3325483T (lt) 2020-01-27
EP3325483A1 (en) 2018-05-30
DK3325483T3 (da) 2020-01-20
AU2023201339A1 (en) 2023-04-06
EP4163284A1 (en) 2023-04-12
CA2991305C (en) 2024-03-12
EP3653628B1 (en) 2022-09-14
KR20180026741A (ko) 2018-03-13
PL3325483T3 (pl) 2020-05-18
IL286788B2 (en) 2024-01-01
WO2017015495A1 (en) 2017-01-26
EP3653628A1 (en) 2020-05-20
AU2021202403A1 (en) 2021-05-20
RU2018105609A3 (sl) 2020-04-30
IL305989A (en) 2023-11-01
US20170051011A1 (en) 2017-02-23
CN108290895A (zh) 2018-07-17
IL256861A (en) 2018-03-29
RU2018105609A (ru) 2019-08-26
KR102660070B1 (ko) 2024-04-24
EP3325483B1 (en) 2019-10-02
EP3325482A1 (en) 2018-05-30
US20230257400A1 (en) 2023-08-17
IL256860A (en) 2018-03-29
IL305279A (en) 2023-10-01
JP6787995B2 (ja) 2020-11-18
HK1252323A1 (zh) 2019-05-24
IL276630A (en) 2020-09-30
KR20240055894A (ko) 2024-04-29
CA2992082A1 (en) 2017-01-26
CY1123390T1 (el) 2022-03-24
IL276631A (en) 2020-09-30
CN113087763A (zh) 2021-07-09
CN108026103B (zh) 2021-04-16
EP3325485B1 (en) 2020-04-08
US10899775B2 (en) 2021-01-26
LT3325482T (lt) 2020-11-25
PT3325482T (pt) 2020-09-24
US20170050986A1 (en) 2017-02-23
US10392407B2 (en) 2019-08-27
CN108055844A (zh) 2018-05-18
US20190112320A1 (en) 2019-04-18
US20190010169A1 (en) 2019-01-10
JP2021035958A (ja) 2021-03-04
CA2991326A1 (en) 2017-01-26
RS60840B1 (sr) 2020-10-30
KR20240055903A (ko) 2024-04-29
ES2764548T3 (es) 2020-06-03
CA3227588A1 (en) 2017-01-26
RU2018105756A3 (sl) 2019-12-23
RU2727151C2 (ru) 2020-07-21
JP6995178B2 (ja) 2022-02-21
US20170050985A1 (en) 2017-02-23
IL283355A (en) 2021-07-29
RU2746322C2 (ru) 2021-04-12
JP6858745B2 (ja) 2021-04-14
KR20180038461A (ko) 2018-04-16
ES2933376T3 (es) 2023-02-06
IL256854A (en) 2018-03-29
WO2017015496A1 (en) 2017-01-26
KR20180038460A (ko) 2018-04-16
RS59806B1 (sr) 2020-02-28
HRP20201479T1 (hr) 2020-12-11
JP2023166434A (ja) 2023-11-21
AU2016297608A1 (en) 2018-02-08
US20180201626A1 (en) 2018-07-19
IL283355B (en) 2022-08-01
WO2017015502A1 (en) 2017-01-26
SG10202009354SA (en) 2020-11-27
US10370389B2 (en) 2019-08-06
US20200017526A1 (en) 2020-01-16
US10787463B2 (en) 2020-09-29
JP2021100959A (ja) 2021-07-08
AU2016297087B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
IL291598A (en) History of benzodiazepine cytotoxicity
IL286788A (en) Methods for the preparation of cytotoxic benzodiazepine compounds
IL287405A (en) Methods for preparing cytotoxic benzodiazepine derivatives
IL293192A (en) Methods for the preparation of indolinobenzodiazepine derivatives
HUP1400545A2 (hu) Eljárás benzazepin származékok elõállítására
GB201513979D0 (en) Synthesis of benzodiazepine derivatives